These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26032168)

  • 1. Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans.
    Babalonis S; Hampson AJ; Lofwall MR; Nuzzo PA; Walsh SL
    J Clin Pharmacol; 2015 Dec; 55(12):1332-43. PubMed ID: 26032168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials.
    Hampson AJ; Babalonis S; Lofwall MR; Nuzzo PA; Krieter P; Walsh SL
    J Clin Psychopharmacol; 2016 Aug; 36(4):324-32. PubMed ID: 27300254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs.
    Morton TL; Devarakonda K; Kostenbader K; Montgomery J; Barrett T; Webster L
    Pain Med; 2016 Mar; 17(3):539-550. PubMed ID: 26304767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.
    Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ
    Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
    Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
    J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
    Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
    Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
    Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
    Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
    Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
    Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of oral dronabinol during opioid withdrawal in humans.
    Jicha CJ; Lofwall MR; Nuzzo PA; Babalonis S; Elayi SC; Walsh SL
    Drug Alcohol Depend; 2015 Dec; 157():179-83. PubMed ID: 26483357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study.
    Singla N; Pong A; Newman K;
    Clin Ther; 2005 Jan; 27(1):45-57. PubMed ID: 15763605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
    Pöyhiä R; Seppälä T; Olkkola KT; Kalso E
    Br J Clin Pharmacol; 1992 Jun; 33(6):617-21. PubMed ID: 1389934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grapefruit juice enhances the exposure to oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model.
    Staahl C; Upton R; Foster DJ; Christrup LL; Kristensen K; Hansen SH; Arendt-Nielsen L; Drewes AM
    J Clin Pharmacol; 2008 May; 48(5):619-31. PubMed ID: 18440921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
    Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
    J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.